scholarly journals FRI0590 Soluble interleukin-2 receptor levels reflect disease activity in IGG4-related disease and primary sjÖgren's syndrome

2017 ◽  
Author(s):  
M Akiyama ◽  
T Sasaki ◽  
Y Kaneko ◽  
H Yasuoka ◽  
K Suzuki ◽  
...  
Keyword(s):  
Disease Activity ◽  
Interleukin 2 ◽  
Sjogren's Syndrome ◽  
Primary Sjögren’S Syndrome ◽  
Primary Sjogren’S Syndrome ◽  
Primary Sjögren's Syndrome ◽  
Related Disease ◽  
Interleukin 2 Receptor ◽  
Igg4 Related Disease ◽  
Soluble Interleukin 2 Receptor

scholarly journals Soluble Interleukin-2 Receptor: A Potential Marker for Monitoring Disease Activity in IgG4-Related Disease

2018 ◽  
Vol 2018 ◽  
pp. 1-6 ◽  
Author(s):  
A. F. Karim ◽  
L. E. M. Eurelings ◽  
R. D. Bansie ◽  
P. M. van Hagen ◽  
J. A. M. van Laar ◽  
...  
Keyword(s):  
Disease Activity ◽  
Interleukin 2 ◽  
Elevated Serum ◽  
Related Disease ◽  
Interleukin 2 Receptor ◽  
Igg4 Related Disease ◽  
Potential Marker ◽  
Potential Biomarker ◽  
Serum Igg4 ◽  
Soluble Interleukin 2 Receptor

Background. IgG4-related disease (IgG4-RD) is a fibroinflammatory condition. T-cells play a crucial role in the pathogenesis, and therefore, serum soluble interleukin-2 receptor (sIL-2R) may be a potential biomarker. Method. We studied the levels of sIL-2R in 26 histologically proven IgG4-RD patients with available serum sIL-2R and compared them to those in newly diagnosed and untreated sarcoidosis patients (n=78) and controls (n=101) and the serum sIL-2R levels in patients after treatment of IgG4-RD (n=15). The disease activity was measured using the IgG4-Related Disease Responder Index (IgG4-RD RI). Results. Median serum sIL-2R in IgG4-RD patients was 4667 pg/ml compared to 1515 pg/ml in controls (P<0.001) and 6050 pg/ml in sarcoidosis patients (P=0.004 compared to IgG4-RD). All IgG4-RD patients had elevated serum sIL-2R levels compared to the reference value of <2500 pg/ml in controls and 85% elevated serum IgG4; however, these did not correlate with each other. Both serum sIL-2R and IgG4 levels declined significantly after treatment (P=0.001 and P=0.01, resp.). Before treatment, serum sIL-2R level and IgG4-RD RI did not correlate with each other. However, the decrease in serum sIL-2R upon treatment did correlate significantly (P=0.04) with the decrease in disease activity assessed by IgG-RD RI. Conclusion. Serum sIL-2R is elevated in IgG4-RD reflecting the inflammatory process with enhanced T-cell activation. Furthermore, serum sIL-2R might serve as a potential marker of response to treatment in IgG4-RD.

Comorbid case of IgG4-related disease and primary Sjögren's syndrome

2014 ◽  
Vol 25 (3) ◽  
pp. 462-467 ◽  
Author(s):  
Yoshikazu Nakashima ◽  
Hideki Nakamura ◽  
Yoshiro Horai ◽  
Tomayoshi Hayashi ◽  
Yukinori Takagi ◽  
...  
Keyword(s):  
Sjögren’S Syndrome ◽  
Sjögren's Syndrome ◽  
Sjogren’S Syndrome ◽  
Sjogren's Syndrome ◽  
Primary Sjögren’S Syndrome ◽  
Primary Sjogren’S Syndrome ◽  
Primary Sjögren's Syndrome ◽  
Related Disease ◽  
Igg4 Related Disease ◽  
Sjögren‘S Syndrome

scholarly journals Clinical features and risk factors of Raynaud’s phenomenon in primary Sjögren’s syndrome

2021 ◽  
Author(s):  
Wei Lin ◽  
Zhifei Xin ◽  
Xiaoran Ning ◽  
Yang Li ◽  
Xiuying Ren ◽  
...  
Keyword(s):  
Risk Factors ◽  
Disease Activity ◽  
Raynaud’S Phenomenon ◽  
Sjogren’S Syndrome ◽  
Raynaud's Phenomenon ◽  
Sjogren's Syndrome ◽  
Primary Sjögren’S Syndrome ◽  
Lung Involvement ◽  
Primary Sjogren’S Syndrome ◽  
Primary Sjögren's Syndrome

Abstract Objective The aim at the current study was to investigate the clinical characteristics and risk factors of Raynaud’s phenomenon (RP) in patients with primary Sjögren’s syndrome (pSS). Methods Retrospective analysis of the medical records of 333 new-onset pSS patients was performed. Demographic, clinical, and serological data were compared between individuals with and without RP. Logistic regression analysis was used to identify risk factors. Results RP was present in 11.41% of the pSS patients. pSS-RP patients were younger (49.74±14.56 years vs. 54.46±13.20 years, p=0.04) and exhibited higher disease activity (11 [5.75–15] vs. 7 [4–12], p=0.03) than those without. The prevalence of lung involvement was significantly higher in pSS patients with RP (60.53% vs. 17.29%; p<0.001). A significantly higher proportion of patients with pSS-RP tested positive about antinuclear (ANA), anti-RNP, and anti-centromere antibodies (ACA) compared to those without (p=0.003, <0.001, and 0.01, respectively). Multivariate analysis identified lung involvement (odds ratio [OR]=8.81, 95% confidence interval [CI] 2.02–38.47; p=0.04), anti-RNP positive status (OR=79.41, 95% CI 12.57–501.78; p<0.0001), as well as ACA (OR=13.17, 95% CI 2.60–66.72; p=0.002) as prognostic factors for pSS-RP. Conclusion The presence of RP defined a subset of pSS with a unique phenotype, manifesting as increased lung involvement and a higher frequency of anti-RNP antibodies and ACA, as well as greater disease activity. These results suggest that RP has clinical and prognostic value of pSS patients. Further prospective studies with a larger number of subjects are warranted to confirm our findings and assess the prognostic and treatment implications of RP in pSS patients. Key Points• Raynaud’s phenomenon (RP) was present in 38 (11.41%) of 333 patients with primary Sjögren’s syndrome (pSS), with patients with RP exhibiting a younger age and higher disease activity.• The presence of RP indicates a subset of pSS with a unique phenotype, with manifestations including increased lung involvement and a higher frequency of anti-RNP antibodies and anti-centromere antibodies.• Patients with pSS and RP need close follow-up and long-term observation (including assessment of microangiopathy), with specific attention paid to the possible development of clinical features of systemic sclerosis.

Sign in / Sign up

Export Citation Format

Share Document